New Promise for Vaccines against Tuberculosis.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Immunogenicity and Safety of the M72/AS01Frontiers in immunology · 2019
   Pooled it
2. Safety and immunogenicity of a thermostable ID93 + GLA-SE tuberculosis vaccine candidate in healthy adults.Nature communications · 2023
   Trial
3. Reinfection as a central constraint on tuberculosis vaccine development.Frontiers in immunology · 2026
   Review
4. Adjunctive beneficial effect of c-di-GMP, a STING agonist, in enhancing protective efficacy of TLR4-adjuvanted tuberculosis subunit vaccine formulations.Journal of biomedical science · 2025
   Article
5. A Mycobacterium tuberculosis-specific subunit vaccine that provides synergistic immunity upon co-administration with Bacillus Calmette-Guérin.Nature communications · 2021
   Article
6. BCG: a vaccine with multiple faces.Human vaccines & immunotherapeutics · 2020
   Review
7. CordingMicroorganisms · 2020
   Article
8. Novel vaccine technologies for the 21st century.Nature reviews. Immunology · 2020
   Review
9. Origin of tuberculosis in the Paleolithic predicts unprecedented population growth and female resistance.Scientific reports · 2020
   Article
10. Rescuing ESAT-6 Specific CD4 T Cells From Terminal Differentiation Is Critical for Long-Term Control of Murine Mtb Infection.Frontiers in immunology · 2020
    Article
11. Research and development of new tuberculosis vaccines: a review.F1000Research · 2018
    Review

Corrections and comments

• Comment on
  Phase 2b Controlled Trial of M72/AS012018

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as